Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Bought by Sheaff Brock Investment Advisors LLC

Sheaff Brock Investment Advisors LLC raised its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 7.7% in the third quarter, Holdings Channel.com reports. The fund owned 7,118 shares of the biopharmaceutical company’s stock after acquiring an additional 507 shares during the period. Sheaff Brock Investment Advisors LLC’s holdings in Halozyme Therapeutics were worth $407,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of HALO. GAMMA Investing LLC lifted its holdings in Halozyme Therapeutics by 96.6% in the 2nd quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 254 shares during the last quarter. International Assets Investment Management LLC purchased a new stake in Halozyme Therapeutics during the second quarter valued at about $33,000. Skandinaviska Enskilda Banken AB publ purchased a new stake in Halozyme Therapeutics during the second quarter valued at about $49,000. Toth Financial Advisory Corp purchased a new stake in Halozyme Therapeutics during the third quarter valued at about $57,000. Finally, FSC Wealth Advisors LLC purchased a new stake in Halozyme Therapeutics during the third quarter valued at about $65,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Halozyme Therapeutics

In other news, CEO Helen Torley sold 10,000 shares of the firm’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $59.20, for a total value of $592,000.00. Following the completion of the sale, the chief executive officer now directly owns 676,744 shares in the company, valued at approximately $40,063,244.80. This trade represents a 1.46 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Over the last three months, insiders sold 70,000 shares of company stock valued at $4,042,500. 2.40% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

HALO has been the subject of a number of analyst reports. Piper Sandler upped their price objective on shares of Halozyme Therapeutics from $51.00 to $52.00 and gave the company a “neutral” rating in a research note on Monday, November 4th. TD Cowen upped their price objective on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. JMP Securities increased their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research report on Friday, November 1st. Finally, Wells Fargo & Company lowered shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and increased their price target for the stock from $58.00 to $62.00 in a research report on Monday, October 7th. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $61.11.

Halozyme Therapeutics Stock Down 15.4 %

Shares of NASDAQ HALO opened at $45.65 on Friday. The stock has a market cap of $5.81 billion, a PE ratio of 15.12, a PEG ratio of 0.54 and a beta of 1.29. The business has a fifty day moving average of $56.04 and a two-hundred day moving average of $53.27. Halozyme Therapeutics, Inc. has a 52-week low of $33.15 and a 52-week high of $65.53. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.